Arrowstreet Capital
HRMY icon

Arrowstreet Capital’s Harmony Biosciences HRMY Stock Holding History

Arrowstreet Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8M Sell
1,312,550
-69,563
-5% -$2.19M 0.02% 582
2026
Q1 		$38.7M Sell
1,382,113
-109,492
-7% -$3.59M 0.02% 568
2025
Q4 		$55.8M Buy
1,491,605
+196,224
+15% +$6.45M 0.03% 451
2025
Q3 		$35.7M Buy
1,295,381
+388,472
+43% +$13.4M 0.02% 557
2025
Q2 		$28.7M Buy
906,909
+508,498
+128% +$16.4M 0.02% 572
2025
Q1 		$13.2M Buy
398,411
+101,793
+34% +$3.65M 0.01% 726
2024
Q4 		$10.2M Sell
296,618
-20,948
-7% -$720K 0.01% 819
2024
Q3 		$12.7M Buy
+317,566
New +$11.2M 0.01% 680
2021
Q2 		– Sell
-17,134
Closed -$566K – 2029
2021
Q1 		$566K Buy
+17,134
New +$601K ﹤0.01% 1965

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's HRMY Position: Q2 2026 in Review

Arrowstreet Capital reduced its Harmony Biosciences (HRMY) stake by 5% in Q2 2026, selling an estimated $2.19M and leaving 1,312,550 shares worth $47.8M. The position accounts for 0.02% of the portfolio, ranked #582.

Arrowstreet Capital first reported a position in HRMY in Q1 2021 and has held it in 9 quarters since. The position peaked at $55.8M in Q4 2025. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Arrowstreet Capital held 1,312,550 shares of Harmony Biosciences worth $47.8M as of Q2 2026.
  • Arrowstreet Capital sold 69,563 Harmony Biosciences shares in Q2 2026, an estimated $2.19M.
  • Harmony Biosciences made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #582 holding.
  • Arrowstreet Capital first reported a position in Harmony Biosciences in Q1 2021 and has held it in 9 quarters since.
  • Arrowstreet Capital's Harmony Biosciences position peaked at $55.8M in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.